Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) EBT: 2019-2025

Historic EBT for Biodesix (BDSX) over the last 6 years, with Sep 2025 value amounting to -$9.1 million.

  • Biodesix's EBT rose 14.17% to -$9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$40.0 million, marking a year-over-year increase of 8.24%. This contributed to the annual value of -$42.8 million for FY2024, which is 15.96% up from last year.
  • According to the latest figures from Q3 2025, Biodesix's EBT is -$9.1 million, which was up 21.45% from -$11.6 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's EBT registered a high of -$6.2 million during Q1 2021, and its lowest value of -$18.8 million during Q1 2023.
  • Moreover, its 3-year median value for EBT was -$10.6 million (2024), whereas its average is -$11.4 million.
  • As far as peak fluctuations go, Biodesix's EBT plummeted by 292.35% in 2021, and later surged by 44.05% in 2023.
  • Over the past 5 years, Biodesix's EBT (Quarterly) stood at -$13.2 million in 2021, then declined by 24.78% to -$16.4 million in 2022, then surged by 44.05% to -$9.2 million in 2023, then grew by 8.67% to -$8.4 million in 2024, then rose by 14.17% to -$9.1 million in 2025.
  • Its EBT stands at -$9.1 million for Q3 2025, versus -$11.6 million for Q2 2025 and -$10.8 million for Q1 2025.